Navigation Links
Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/29/2008

BRIDGEWATER, N.J., May 29 /PRNewswire/ -- Ortho Biotech today announced that two clinical studies for DOXIL(R) (doxorubicin HCl pegylated liposome injection) will be presented at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago from May 30 to June 3, 2008.

"We are pleased that ASCO has accepted these data for presentation at the annual meeting," said Craig Tendler, M.D., Vice President, Medical Affairs, Oncology/Nephrology, Ortho Biotech Products, L.P. "Through our ongoing investigation of DOXIL, Ortho Biotech is committed to oncology clinical research and helping patients fight cancer."
Data from the following studies will be presented:

-- The Effect of Pegylated Liposomal Doxorubicin Plus Bortezomib in

Multiple Myeloma Patients with Renal Insufficiency (Abstract 8562)

Presentation: Saturday, May 31, 8:00 am - 12:00 pm CST, General

Poster Session: Lymphoma and Plasma Cell Disorders, S Hall A1,

Poster 47A

Authors: J. Blade, P. Sonneveld, J. San Miguel, H. Sutherland,

R. Hajek, A. Nagler, A. Spencer, T. Robak, J. L. Harousseau,

R. Z. Orlowski, The DOXIL-MMY-3001 Study Investigators

-- Phase II Trial of Pegylated Liposomal Doxorubicin (PLD), Rituxan,

Cyclophosphamide, Vincristine, and Prednisone in Aggressive B-Cell

Non-Hodgkin's Lymphoma (Abstract 8563)

Presentation: Saturday, May 31, 8:00 am - 12:00 pm CST, General

Poster Session: Lymphoma and Plasma Cell Disorders, S Hall A1,

Poster 47B

Authors: H. Gu, A. Tulpule, N. Berman, C. Duran, S. G. Groshen,

L. Buchanan, W. Boswell, B. Nathwani, A. M. Levine

In addition, the following study was accepted for publication:

-- Activity and Toxicity of Pegylated Liposomal Doxorubicin in

Combination Regimen (DRCOP) for Patients >60 Years Old With Untreate
'/>"/>

SOURCE Ortho Biotech
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
2. Genmab Announces Updates on Phase III Cancer Studies
3. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
4. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
5. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
6. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
9. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
10. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
11. Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...HAM,Mass.,Nov.25/PRNewswire/--AccordingtoMillenniu...hnologymarketintelligence,thenearly$3billionUSmark...owthoverthenextfiveyearsdespitetherecenteconomicsl...tfindsthatthismarketwillremainhighlydynamicoverthe...ddevicesinpreviouslyunderservedsegmentsofthetrauma...
(Date:11/25/2009)...T,TheNetherlandsandJOHANNESBURG,November25/PRNewsw...xisDiscoveryannouncedtoday,thattheyhavesignedacoll...rvices. , Pyxis,sworldclasscomputationalchemi...emba,sservicedivisiontoprovidemedicinaland,synthet...,internationalclientnetwork.iThembaPharmaceutical...
(Date:11/24/2009)...NE,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix,...eatmentsforaorticdisorders,announcedtodaythatithas...hepatentinfringementlawsuitbroughtagainstitinOctob...sDistrictCourtinIndianapolis,Indiana. ,, Endolo...itedStatesPatentandTrademarkOffice(USPTO)conductsp...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 1AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 2AMA Honors Medical Society Executives 60901 1AMA Honors Medical Society Executives 60901 2AMA Has Chance to Rescind Support of HR 3962 3B AMA Shout Out from Public Urges Doctors to Answer to PATIENTS Not AMA Leadership 60899 1
...--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeuti...om a Phase 3 clinical trial,of Fampridine-SR in pe...Academy of Neurology meeting. Andrew Goodman, M.D.... University of,Rochester, presented top-line resul...d clinician and subject global impressions.,Dr. Go...
...OD CITY, Calif., May 02, 2007 /PRNewswire-FirstCal...that a presentation was,made today at the 20th Int...held in Palm Springs, California, on a,non-nucleos...iscovered by Genelabs. , The oral presentation was...of Medicinal Chemistry at Genelabs, entitled,"GL59...
Other Medicine Technology:Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:11/27/2009)...all/--TheGymboreeCorporation(Nasdaq: GYMB )announc...MX23rdInvestorProgram,whichwillbeheldattheMayFairH...11:45a.m.GMT. ,, TolistentoalivebroadcastofTheG...easelogontowww.gymboree.com,clickon"OurCompany"att...ndthen"ConferenceCalls&Webcasts."Thewebcastwil...
(Date:11/27/2009)...e-FirstCall/--ShamirOpticalIndustryLtd.(Nasdaq: SH...ctsandtechnologytotheophthalmiclensmarket,announce...istributioninanaggregateamountofUS$10million(appro...presentativerateofexchange),orapproximatelyUS$0.60...esentativerateofexchange)perordinarysharebasedonth...
(Date:11/27/2009)... economic burdens, study predicts , , FR...ople with diabetes in the United States is expecte...edicts. , That would bring the total by 2034 to...om 23.7 million today. , , At the same time, the..., the study also warns, rising from an estimated $...
(Date:11/27/2009)...gual coloring books designed for children ages 2 t...o educate - inform parents and children alike on a...rs to ABC,S and a host of other topics. , ...27, 2009 -- Today’s children have enough gad...ur of the day, but one of the oldest and simplest ...
(Date:11/26/2009)...ndfluseasonuponus,it,smoreimportantthanevertoemplo...idillness. ,, "Weneedtobeproactivenotonlytokeep...,resick,"saidEileenFinerty,RN,MS,CIC(certifiedinin...landoccupationalhealthatHospitalforSpecialSurgery(...soneofthelowestinfectionratesofanyhospitalinthecou...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...swire/ -- WuXi PharmaTech (NYSE:,WX), a leading ph...earch,and development outsourcing company with ope...o announce that the distinguished Stanford Univers...: http://www.newscom.com/cgi-bin/prnh/20040705/CN...
... May 20 Accelerate Brain Cancer,Cure ( http://www...on its,website from leading brain cancer specialis...rain cancer study, as well as valuable guidance fo...ain cancer research and treatment,including:, Dr....
...linic researchers found that the frequency with wh...ssociated pneumonia (VAP) is approximately the sam...yo Clinic compared to the average VAP-risk rate fo...rong across the U.S. in intensive care units, whic...
...scious after swallowing Aqua Dots beads led to a v...t the time, it was widely reported that the potent...used in place of the benign but more expensive 1,5...eports, finding that Aqua Dots contained no 1,5-PD...
...wire/.- Speaker Nancy Pelosi,issued the following ...ennedy,s health:, "The news of Senator Kennedy,s ... Kennedy is a champion for health care for all Ame...e., "Our thoughts and prayers are with him, with ...
... draws specialists from across the ...al Werks, a leading provider of,ceramic components...ices,announced today that the Company will provide...,of disorders of the spine will convene at the Pal...
Other Medicine News:Health News:Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars 2Health News:Brain Cancer Science and Treatment Information 2Health News:Intensive care units' prevention of pneumonia in critically-ill patients generally strong 2Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland 2
Access Vitamin B12
...ked immunosorbent assay (ELISA) for the semi-quant... in human serum. The presence of ANA can be used i...oratory tests to aid in the diagnosis of rheumatic...gren's syndrome, scleroderma, and mixed connective...
...s that are compatible with multichannel pipettors,...ber of pipetting steps required to prepare and pla... Immuno Concepts for more information about this p... noted with an * after the catalog number and are ...
... to screen out patients negative for antinuclear a...mic rheumatic diseases such as Systemic lupus eryt...tive tissue disease, progressive systemic sclerosi... Raynaud's phenomenon. They can also be used in co...
Medicine Products: